GSK plc
Get $10 bonus on your first $100 deposit for GS7.DE
Get $10 bonus on your first $100 deposit for GS7.DE
GSK plc (GS7.DE) Stock Competitors & Peer Comparison
See (GS7.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GS7.DE | €20.60 | +25.00% | 0 | 17.31 | €1.19 | N/A |
| LLY.DE | €772.20 | -2.61% | 729.6B | 39.26 | €19.67 | +0.68% |
| JNJ.DE | €201.50 | -1.27% | 485.3B | 21.50 | €9.37 | +2.18% |
| 4AB.DE | €175.40 | -0.71% | 310.2B | 86.83 | €2.02 | +3.24% |
| ZEG.DE | €160.70 | +0.59% | 249.2B | 28.75 | €5.59 | +1.69% |
| 6MK.DE | €99.45 | -2.40% | 245.9B | 15.94 | €6.24 | +2.79% |
| AMG.DE | €293.20 | -1.30% | 158.1B | 23.99 | €12.22 | +2.78% |
| GIS.DE | €117.60 | -1.23% | 146B | 20.28 | €5.80 | +2.30% |
| PFE.F | €22.96 | -0.09% | 131.5B | 19.76 | €1.17 | +6.36% |
| PFE.DE | €22.96 | -0.69% | 130.6B | 19.79 | €1.16 | +6.35% |
Stock Comparison
GS7.DE vs LLY.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, LLY.DE has a market cap of 729.6B. Regarding current trading prices, GS7.DE is priced at €20.60, while LLY.DE trades at €772.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas LLY.DE's P/E ratio is 39.26. In terms of profitability, GS7.DE's ROE is +0.34%, compared to LLY.DE's ROE of +0.98%. Regarding short-term risk, GS7.DE is more volatile compared to LLY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check LLY.DE's competition here
GS7.DE vs JNJ.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, JNJ.DE has a market cap of 485.3B. Regarding current trading prices, GS7.DE is priced at €20.60, while JNJ.DE trades at €201.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas JNJ.DE's P/E ratio is 21.50. In terms of profitability, GS7.DE's ROE is +0.34%, compared to JNJ.DE's ROE of +0.34%. Regarding short-term risk, GS7.DE is more volatile compared to JNJ.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check JNJ.DE's competition here
GS7.DE vs 4AB.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, 4AB.DE has a market cap of 310.2B. Regarding current trading prices, GS7.DE is priced at €20.60, while 4AB.DE trades at €175.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas 4AB.DE's P/E ratio is 86.83. In terms of profitability, GS7.DE's ROE is +0.34%, compared to 4AB.DE's ROE of -3.62%. Regarding short-term risk, GS7.DE is more volatile compared to 4AB.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check 4AB.DE's competition here
GS7.DE vs ZEG.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, ZEG.DE has a market cap of 249.2B. Regarding current trading prices, GS7.DE is priced at €20.60, while ZEG.DE trades at €160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas ZEG.DE's P/E ratio is 28.75. In terms of profitability, GS7.DE's ROE is +0.34%, compared to ZEG.DE's ROE of +0.23%. Regarding short-term risk, GS7.DE is more volatile compared to ZEG.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check ZEG.DE's competition here
GS7.DE vs 6MK.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, 6MK.DE has a market cap of 245.9B. Regarding current trading prices, GS7.DE is priced at €20.60, while 6MK.DE trades at €99.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas 6MK.DE's P/E ratio is 15.94. In terms of profitability, GS7.DE's ROE is +0.34%, compared to 6MK.DE's ROE of +0.36%. Regarding short-term risk, GS7.DE is more volatile compared to 6MK.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check 6MK.DE's competition here
GS7.DE vs AMG.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, AMG.DE has a market cap of 158.1B. Regarding current trading prices, GS7.DE is priced at €20.60, while AMG.DE trades at €293.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas AMG.DE's P/E ratio is 23.99. In terms of profitability, GS7.DE's ROE is +0.34%, compared to AMG.DE's ROE of +0.97%. Regarding short-term risk, GS7.DE is more volatile compared to AMG.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check AMG.DE's competition here
GS7.DE vs GIS.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, GIS.DE has a market cap of 146B. Regarding current trading prices, GS7.DE is priced at €20.60, while GIS.DE trades at €117.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas GIS.DE's P/E ratio is 20.28. In terms of profitability, GS7.DE's ROE is +0.34%, compared to GIS.DE's ROE of +0.41%. Regarding short-term risk, GS7.DE is more volatile compared to GIS.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check GIS.DE's competition here
GS7.DE vs PFE.F Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, PFE.F has a market cap of 131.5B. Regarding current trading prices, GS7.DE is priced at €20.60, while PFE.F trades at €22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas PFE.F's P/E ratio is 19.76. In terms of profitability, GS7.DE's ROE is +0.34%, compared to PFE.F's ROE of +0.09%. Regarding short-term risk, GS7.DE is more volatile compared to PFE.F. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check PFE.F's competition here
GS7.DE vs PFE.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, PFE.DE has a market cap of 130.6B. Regarding current trading prices, GS7.DE is priced at €20.60, while PFE.DE trades at €22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas PFE.DE's P/E ratio is 19.79. In terms of profitability, GS7.DE's ROE is +0.34%, compared to PFE.DE's ROE of +0.09%. Regarding short-term risk, GS7.DE is more volatile compared to PFE.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check PFE.DE's competition here
GS7.DE vs BRM.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BRM.DE has a market cap of 99.7B. Regarding current trading prices, GS7.DE is priced at €20.60, while BRM.DE trades at €48.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BRM.DE's P/E ratio is 16.51. In terms of profitability, GS7.DE's ROE is +0.34%, compared to BRM.DE's ROE of +0.39%. Regarding short-term risk, GS7.DE is more volatile compared to BRM.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check BRM.DE's competition here
GS7.DE vs SNW.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, SNW.DE has a market cap of 97.6B. Regarding current trading prices, GS7.DE is priced at €20.60, while SNW.DE trades at €81.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas SNW.DE's P/E ratio is 20.13. In terms of profitability, GS7.DE's ROE is +0.34%, compared to SNW.DE's ROE of +0.15%. Regarding short-term risk, GS7.DE is more volatile compared to SNW.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check SNW.DE's competition here
GS7.DE vs BAYN.SG Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BAYN.SG has a market cap of 40.2B. Regarding current trading prices, GS7.DE is priced at €20.60, while BAYN.SG trades at €40.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BAYN.SG's P/E ratio is N/A. In terms of profitability, GS7.DE's ROE is +0.34%, compared to BAYN.SG's ROE of -0.12%. Regarding short-term risk, GS7.DE is more volatile compared to BAYN.SG. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check BAYN.SG's competition here
GS7.DE vs BAYN.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BAYN.DE has a market cap of 40B. Regarding current trading prices, GS7.DE is priced at €20.60, while BAYN.DE trades at €40.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BAYN.DE's P/E ratio is -11.07. In terms of profitability, GS7.DE's ROE is +0.34%, compared to BAYN.DE's ROE of -0.12%. Regarding short-term risk, GS7.DE is more volatile compared to BAYN.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check BAYN.DE's competition here
GS7.DE vs IDP.DE Comparison April 2026
GS7.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, IDP.DE has a market cap of 22.3B. Regarding current trading prices, GS7.DE is priced at €20.60, while IDP.DE trades at €151.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas IDP.DE's P/E ratio is 20.16. In terms of profitability, GS7.DE's ROE is +0.34%, compared to IDP.DE's ROE of +0.07%. Regarding short-term risk, GS7.DE is more volatile compared to IDP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GS7.DE.Check IDP.DE's competition here